Lilly Liver-Treatment Candidate Meets Clinical Targets
April 04 2018 - 9:19AM
Dow Jones News
By Bowdeya Tweh
Eli Lilly & Co. (LLY) said Wednesday results from a
late-stage trial of a liver-cancer treatment met clinical targets,
moving the company toward making regulatory submissions for the
drug later this year.
Indianapolis-based Lilly said its study of Cyramza, or
ramucirumab, as a second-line treatment of hepatocellular carcinoma
met its primary endpoint of overall survival as well as a secondary
endpoint of progression-free survival. Studies of Cyramza have
enrolled more than 12,000 patients in more than 70 trials
world-wide, Lilly said.
Lilly said it plans to start regulatory submissions for Cyramza
in mid-2018. Liver cancer is the sixth most common cancer
world-wide and the second-leading cause of cancer-related death,
the company said.
Lilly also said Wednesday it has reached a deal with privately
held biopharmaceutical company to develop therapies to potentially
treat type 1 diabetes. In the partnership between Lilly and
Cambridge, Mass.-based Sigilon Therapeutics, Sigilon will develop
products made of a type of stem cell that can restore insulin
production over sustained periods, without triggering an immune
reaction, Lilly said.
Sigilon will receive an upfront payment of $63 million and Lilly
will make an undisclosed equity investment in Sigilon. Sigilon will
be eligible to receive up to $410 million based on reaching certain
development and commercialization milestones. Sigilon could also
receive royalties on future product sales, Lilly said.
Lilly said the Sigilon transaction will dent earnings by 5 cents
a share in the second quarter.
Write to Bowdeya Tweh at bowdeya.tweh@wsj.com
(END) Dow Jones Newswires
April 04, 2018 09:04 ET (13:04 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Apr 2023 to Apr 2024